#Paris #France #medical technology #Echosens #Romain Baujard

Echosens Welcomes Romain Baujard as CEO

On April 28, 2026, Echosens, a prominent global diagnostics company specializing in non-invasive medical devices, announced the appointment of Romain Baujard as its new Chief Executive Officer (CEO), effective May 1, 2026. He takes over from Dominique Legros, who has retired after leading the company since 2019. Under Legros's leadership, Echosens witnessed a remarkable period of global expansion and growing acceptance of its revolutionary technology.

A New Chapter for Echosens

With an aim to significantly enhance liver health as a central aspect of cardiometabolic care, Echosens is ready to enter a new phase of growth. The shift aligns with rising global metabolic disease prevalence and rapid treatment innovations, indicating a rising need for solutions in early detection and long-term disease management. This strategic pivot is backed by partnerships with Inner Mongolia FuRui Medical Science – a high-tech health company dedicated to liver disease management – and Astorg, a leading European private equity firm with extensive healthcare experience.

Romain Baujard joined Echosens in 2015 and has excelled in various strategic and operational roles, including as Vice President of Pharma. His track record involves overseeing global marketing, international trade operations, and forging partnerships with top pharmaceutical companies, thereby solidifying Echosens’s position at the intersection of liver health and emerging cardiometabolic therapies.

Baujard's Vision for the Future

Commenting on his new role, Baujard expressed his enthusiasm: "I am honored to take on this responsibility. Echosens stands at a pivotal juncture as innovation within cardiometabolic care accelerates. Assessing liver health is becoming increasingly vital in patient evaluation and treatment. Our opportunity lies in embedding liver examination into routine care on a large scale."

He added, "We aim to expand access to our technologies and support clinicians beyond traditional specialties, enhancing our digital, data-driven, and AI capabilities to enable earlier detection and more effective risk management."

A Tribute to Dominique Legros

Dominique Legros leaves behind a legacy marked by strong growth and transformational advancement for Echosens. Under his guidance, the FibroScan® technology expanded beyond hepatology and gastroenterology into disciplines like diabetology and endocrinology, affirming the rising recognition of liver health as a crucial component of broader metabolic management strategies.

Legros stated, "Leading Echosens has been a privilege. Our focus has always been on enabling healthcare professionals to make better clinical decisions and improve patient outcomes. Liver health is critical, and I’m proud of our teams for driving this message into global treatment pathways. I am confident that Romain is the right leader to navigate Echosens through its next growth phase."

Stakeholder Support and Future Direction

Echosens stakeholders, along with Chairman and co-founder Laurent Sandrin, acknowledged Legros's contributions, emphasizing the strong platform built under his leadership with growing clinical acceptance and global reach.

Echosens is recognized as a leader in non-invasive liver health assessment solutions, leveraging its FibroScan® technology and expanding digital ecosystem to position liver health as an essential marker in cardiometabolic care.

Looking forward, the collaboration with Inner Mongolia FuRui Medical Science and continued support from Astorg will undoubtedly facilitate Echosens's nationwide and global reach in liver disease management, opening doors to substantial advancements in healthcare.

About Echosens

Echosens is a world leader in providing non-invasive solutions for liver health assessment. With a commitment to establishing liver health as paramount in cardiometabolic care, the company seeks innovative paths to improve patient outcomes and public health.

Inner Mongolia FuRui Medical Science Co, Ltd.

Inner Mongolia FuRui Medical Science, established in 1998 and headquartered in Beijing, is dedicated to the prevention, diagnosis, treatment, and long-term management of liver diseases. The company emphasizes a patient-centric approach with an integrated managed-care model, comprising non-invasive diagnostics, pharmaceutical therapies, and digital health services.

About Astorg

Astorg is a leading European private equity firm, managing over €23 billion in assets. It partners with entrepreneurs and management teams to acquire and enhance market-leading companies, driving growth through strategic guidance and financial support, particularly in healthcare and technology sectors.

In summary, Echosens's future looks bright under the new leadership of Romain Baujard, as the company aims to leverage technology and collaboration at the forefront of liver health diagnostics.